Results validate potential as the first prophylactic therapy to address the heavy physical and psychosocial burden of Glanzmann thrombasthenia; Phase 3 registration study planned for 2026 CAMBRIDGE, ...
With a $157 million series C funding round, Hemab Therapeutics is looking to infuse innovation into the treatment landscape for rare and underserved bleeding disorders. The oversubscribed series C was ...
Sutacimig is being developed as the first-ever prophylactic treatment for Glanzmann thrombasthenia (GT), a serious and potentially life-threatening bleeding disorder affecting patients worldwide. The ...
A 35-year-old primigravid woman had a dichorionic diamniotic twin pregnancy with Glanzmann thrombasthenia (GT). She underwent elective caesarean section (CS) under general anaesthesia at 36 + 5 weeks ...
Background: In human medicine, nucleated red blood cells (NRBCs) in the peripheral blood have been associated with a poor prognosis and increased mortality in critically ill patients. In critically ...
Abstract: The accurate classification of cancer cells in the peripheral blood is essential for the diagnosis of leukemia and has traditionally been carried out by analyzing laboratory images. In this ...
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma Allogeneic hematopoietic stem cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback